{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T14:43:09Z","timestamp":1772548989968,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.ajo.2013.02.001","type":"journal-article","created":{"date-parts":[[2013,3,28]],"date-time":"2013-03-28T20:05:26Z","timestamp":1364501126000},"page":"173-177.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Long-term Botulinum Toxin Treatment of Benign Essential Blepharospasm, Hemifacial Spasm, and Meige Syndrome"],"prefix":"10.1016","volume":"156","author":[{"given":"Craig N.","family":"Czyz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas P.","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth V.","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill A.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ajo.2013.02.001_bib1","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/mds.21084","article-title":"Prevalence of primary blepharospasm in Sardinia, Italy: a service-based survey","volume":"21","author":"Cossu","year":"2006","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.ajo.2013.02.001_bib2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00702-007-0768-7","article-title":"Botulinum toxin in the treatment of blepharospasm and hemifacial spasm","volume":"115","author":"Kenney","year":"2008","journal-title":"J Neural Transm"},{"issue":"3","key":"10.1016\/j.ajo.2013.02.001_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.iio.0000167238.26526.a8","article-title":"Benign essential blepharospasm","volume":"45","author":"Ben Simon","year":"2005","journal-title":"Int Ophthalmol Clin"},{"issue":"9","key":"10.1016\/j.ajo.2013.02.001_bib4","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/archneur.1986.00520090006004","article-title":"Blepharospasm with basal ganglia lesions","volume":"43","author":"Jankovic","year":"1986","journal-title":"Arch Neurol"},{"issue":"9","key":"10.1016\/j.ajo.2013.02.001_bib5","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1212\/WNL.33.9.1237","article-title":"Blepharospasm associated with brainstem lesions","volume":"33","author":"Jankovic","year":"1983","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ajo.2013.02.001_bib6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/mds.870010107","article-title":"Ipsilateral blepharospasm and contralateral hemidystonia and parkinsonism in a patient: CT, MRI and PET scanning","volume":"1","author":"Leenders","year":"1986","journal-title":"Mov Disord"},{"issue":"9","key":"10.1016\/j.ajo.2013.02.001_bib7","first-page":"837","article-title":"Cranial dystonia, blepharospasm and hemifacial spasm: clinical features and treatment, including the use of botulinum toxin","volume":"139","author":"Kraft","year":"1988","journal-title":"CMAJ"},{"issue":"6","key":"10.1016\/j.ajo.2013.02.001_bib8","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/jnnp.51.6.767","article-title":"Blepharospasm: a review of 264 patients","volume":"51","author":"Grandas","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.ajo.2013.02.001_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-1331.2010.03042.x","article-title":"EFNS guidelines on diagnosis and treatment of primary dystonias","volume":"18","author":"Albanese","year":"2011","journal-title":"Eur J Neurol"},{"issue":"Suppl 1","key":"10.1016\/j.ajo.2013.02.001_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1468-1331.2010.03045.x","article-title":"Craniocervical dystonia: clinical and pathophysiological features","volume":"17","author":"Colosimo","year":"2010","journal-title":"Eur J Neurol"},{"issue":"19","key":"10.1016\/j.ajo.2013.02.001_bib11","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","article-title":"Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence based review): report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology","volume":"70","author":"Simpson","year":"2008","journal-title":"Neurology"},{"issue":"Suppl 8","key":"10.1016\/j.ajo.2013.02.001_bib12","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1002\/mds.20020","article-title":"Basic immunological aspects of botulinum toxin therapy","volume":"19","author":"Atassi","year":"2004","journal-title":"Mov Disord"},{"issue":"10","key":"10.1016\/j.ajo.2013.02.001_bib13","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mds.22157","article-title":"Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay","volume":"23","author":"Brin","year":"2008","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.ajo.2013.02.001_bib14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mds.870090216","article-title":"Development of resistance to botulinum toxin type A in patients with torticollis","volume":"9","author":"Greene","year":"1994","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.ajo.2013.02.001_bib15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/mds.10659","article-title":"Long-term follow-up of cervical dystonia patients treated with botulinum toxin A","volume":"19","author":"Haussermann","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.ajo.2013.02.001_bib16","first-page":"67","article-title":"Clinical features, differential diagnosis and pathogenesis of blepharospasm and cranial-cervical dystonia","volume":"4","author":"Jankovic","year":"1985","journal-title":"Adv Ophthalmic Plast Reconstr Surg"},{"issue":"4","key":"10.1016\/j.ajo.2013.02.001_bib17","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ana.410130406","article-title":"Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients","volume":"13","author":"Jankovic","year":"1983","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ajo.2013.02.001_bib18","first-page":"351","article-title":"Dystonia: the spectrum of the disease","volume":"55","author":"Marsden","year":"1976","journal-title":"Res Publ Assoc Res Nerv Ment Dis"},{"issue":"11","key":"10.1016\/j.ajo.2013.02.001_bib19","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/archneur.1990.00530110095023","article-title":"Hemifacial spasm in Rochester and Olmsted County, Minnesota, 1960 to 1984","volume":"47","author":"Auger","year":"1990","journal-title":"Arch Neurol"},{"issue":"6","key":"10.1016\/j.ajo.2013.02.001_bib20","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/jnnp.64.6.751","article-title":"Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases","volume":"64","author":"Jitpimolmard","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.ajo.2013.02.001_bib21","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/mds.20376","article-title":"Long-term botulinum toxin efficacy, safety, and immunogenicity","volume":"20","author":"Mejia","year":"2005","journal-title":"Mov Disord"},{"issue":"12","key":"10.1016\/j.ajo.2013.02.001_bib22","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0161-6420(95)30757-9","article-title":"Long-term changes in duration of relief with botulinum toxin treatment of essential blepharospasm and hemifacial spasm","volume":"102","author":"Ainsworth","year":"1995","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2013.02.001_bib23","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1001\/archneur.59.3.418","article-title":"Botulinum toxin A treatment for primary hemifacial spasm. A 10-year multicenter study","volume":"59","author":"Defazio","year":"2002","journal-title":"Arch Neurol"},{"issue":"6","key":"10.1016\/j.ajo.2013.02.001_bib24","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/mds.10252","article-title":"Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period","volume":"17","author":"Hsiung","year":"2002","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.ajo.2013.02.001_bib25","first-page":"363","article-title":"Long-term treatment of blepharospasm with botulinum toxin type A","volume":"4","author":"Nussgens","year":"1995","journal-title":"Ger J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2013.02.001_bib26","first-page":"7","article-title":"Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides","volume":"29","author":"Matarasso","year":"2003","journal-title":"Dermatol Surg"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939413001037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939413001037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:08:32Z","timestamp":1757596112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939413001037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0002939413001037"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2013.02.001","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term Botulinum Toxin Treatment of Benign Essential Blepharospasm, Hemifacial Spasm, and Meige Syndrome","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2013.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}